You are here

Eli Lilly

Eli Lilly bets $1B in biobucks on Haya to scour dark genome for obesity targets

Fierce Biotech

Wed, 09/4/24 - 11:37 am

Haya Therapeutics

New research could ease concerns over suicide risk of obesity drugs

BioPharma Dive

Tue, 09/3/24 - 05:58 pm

Eli Lilly partner Hutchmed scraps China stomach cancer filing as approval seems unlikely

Fierce Pharma

Fri, 08/30/24 - 11:40 am

Eli Lilly’s lauded discount of its obesity drug Zepbound comes with caveats

Stat

Wed, 08/28/24 - 09:24 pm

Eli Lilly rolls out direct patient access to weight loss star Zepbound—at a deep discount

Fierce Pharma

Tue, 08/27/24 - 11:51 am

Lilly launches smallest single-dose vials of Zepbound for $399

Reuters

Tue, 08/27/24 - 11:16 am

Mixed reactions among HCPs as lecanemab and donanemab secure FDA approval for Alzheimer's treatment

Pharmaphorum

Mon, 08/26/24 - 10:14 am

Alzheimer's disease

Eli Lilly seeks new angle on high-value target, tapping Oblique for antibody discovery push

Fierce Biotech

Thu, 08/22/24 - 11:55 am

Oblique Therapeutics

Lilly’s tirzepatide cuts diabetes risk, study data show

BioPharma Dive

Tue, 08/20/24 - 11:54 am

type 2 diabetes

clinical trials

After Europe deal, Organon pays $22.5M to expand Emgality marketing pact with Lilly

Fierce Pharma

Tue, 08/20/24 - 11:34 am

'We're pretty prolific': Lilly Catalyze360 looks to connect with emerging biotechs across 'all areas'

Fierce Biotech

Mon, 08/19/24 - 11:10 am

Lilly Catalyze360

business development

Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived

Motley Fool

Sun, 08/18/24 - 09:19 pm

Lilly demands doctors stop selling copycat weight-loss drugs

Reuters

Thu, 08/15/24 - 11:50 am

drug counterfeiting

Eli Lilly unwraps $700M nucleic acid R&D center in Boston Seaport, opens doors to biotechs

Fierce Biotech

Tue, 08/13/24 - 11:49 am

Weight-loss drugs like Wegovy may help stave off some cancers

NPR

Mon, 08/12/24 - 11:28 am

Pharma execs react to final drug price negotiations with Medicare

Pharma Voice

Fri, 08/9/24 - 11:21 am

Inflation Reduction Act

Bristol Myers Squibb

Lilly's tau drug for Alzheimer's flunks phase 2 test

Pharmaphorum

Fri, 08/9/24 - 11:18 am

Alzheimer's disease

clinical trials

Lilly boosts outlook on rising Zepbound revenue

BioPharma Dive

Thu, 08/8/24 - 11:19 am

Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half

Pharma Voice

Thu, 08/8/24 - 11:07 am

Pages